Ana Vitória Pupo Silvestrini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ana Vitória Pupo Silvestrini has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Maria Vitória Lopes Badra Bentley
University of São Paulo
5 shared publications - Juliana Santos Rosa Viegas
School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo, Brazil
3 shared publications - Angelo Luis Caron
School of Pharmaceutical Sciences of Ribeirao Preto, University of Sao Paulo, Av. do Café s/n, Ribeirao Preto, SP, 14040-903, Brazil
2 shared publications - Fabiola Garcia Praça
University of São Paulo
2 shared publications - Maurício Ventura Mazzi
Graduate Program of Biomedical Sciences, University Center of Hermínio Ometto Foundation–FHO, Araras, SP, Brazil
2 shared publications - Acácio Antônio Pigoso
Graduate Program in Biomedical Sciences Hermínio Ometto University Center, FHO-UNIARARAS, Av. Dr. Maximiliano Baruto, 500, CEP 13607-339 Araras, SP, Brazil
1 shared publication
Latest Publications
- Open Access
- 9 May 2026
- Published by Springer Nature in Clinical Reviews in Allergy & Immunology
- Vol. 69 (1) , 42
Vitiligo as a Failure of Immune Resolution and Tissue Regeneration: From Stress Signals to Targeted Immune Modulation
Traditionally, vitiligo is known as a cutaneous autoimmune disease characterized by progressive melanocyte loss. However, this paradigm alone does not fully explain disease chronicity, relapse, or the limited therapeutic responses. Evidence supports a broader conceptual framework in which vitiligo is sustained by defective immune control of dysregulated responses, coupled with impaired regeneration, resulting in persistent inflammation and failure to restore cutaneous homeostasis. Here, we reinterpret vitiligo immunopathogenesis as a disorder of failed restoration of immunological homeostasis, extending beyond classical immune activation to include defects in regulatory mechanisms that normally constrain autoreactive responses. Rather than focusing exclusively on broad immunosuppression, emerging strategies increasingly aim to restore local immune regulation, constrain pathogenic immune memory, and preserve or reconstitute melanocyte regenerative niches. Advances in cutaneous immunology and biotechnology have expanded the therapeutic landscape to include targeted cytokine and kinase inhibition, immune checkpoint modulation, pro-melanogenic and regenerative approaches, cell- and vesicle-based therapies, nucleic acid-based interventions, and advanced skin delivery systems. Accumulating knowledge supports combined and sequential treatment paradigms integrating immune modulation, induction of repigmentation, and long-term maintenance. Nevertheless, translation into routine clinical practice remains limited by cutaneous pharmacokinetic barriers, regulatory and manufacturing constraints, and the lack of long-term safety and efficacy data. Within this evolving landscape, precision medicine offers a framework for patient stratification, therapeutic timing, and rational treatment design. Importantly, many of these approaches remain in early or preclinical stages, highlighting the need for robust translational validation. On the other hand, delivery platforms based on nanotechnology emerge as potential tools capable of bridging diverse therapeutic modalities by enhancing stability, targeting, and cutaneous bioavailability. Finally, this review positions vitiligo as a disease of failed immune resolution and impaired tissue regeneration, highlighting precision immunoengineering and technological innovation as promising pathways toward more targeted, personalized, and durable disease-modifying therapies.
- 9 May 2026
- Published by Springer Nature in Clinical Reviews in Allergy & Immunology
- Vol. 69 (1) , 42
Open AccessVitiligo as a Failure of Immune Resolution and Tissue Regeneration: From Stress Signals to Targeted Immune Modulation
Traditionally, vitiligo is known as a cutaneous autoimmune disease characterized by progressive melanocyte loss. However, this paradigm alone does not fully explain disease chronicity, relapse, or the limited therapeutic responses. Evidence supports a broader conceptual framework in which vitiligo is sustained by defective immune control of dysregulated responses, coupled with impaired regeneration, resulting in persistent inflammation and failure to restore cutaneous homeostasis. Here, we reinterpret vitiligo immunopathogenesis as a disorder of failed restoration of immunological homeostasis, extending beyond classical immune activation to include defects in regulatory mechanisms that normally constrain autoreactive responses. Rather than focusing exclusively on broad immunosuppression, emerging strategies increasingly aim to restore local immune regulation, constrain pathogenic immune memory, and preserve or reconstitute melanocyte regenerative niches. Advances in cutaneous immunology and biotechnology have expanded the therapeutic landscape to include targeted cytokine and kinase inhibition, immune checkpoint modulation, pro-melanogenic and regenerative approaches, cell- and vesicle-based therapies, nucleic acid-based interventions, and advanced skin delivery systems. Accumulating knowledge supports combined and sequential treatment paradigms integrating immune modulation, induction of repigmentation, and long-term maintenance. Nevertheless, translation into routine clinical practice remains limited by cutaneous pharmacokinetic barriers, regulatory and manufacturing constraints, and the lack of long-term safety and efficacy data. Within this evolving landscape, precision medicine offers a framework for patient stratification, therapeutic timing, and rational treatment design. Importantly, many of these approaches remain in early or preclinical stages, highlighting the need for robust translational validation. On the other hand, delivery platforms based on nanotechnology emerge as potential tools capable of bridging diverse therapeutic modalities by enhancing stability, targeting, and cutaneous bioavailability. Finally, this review positions vitiligo as a disease of failed immune resolution and impaired tissue regeneration, highlighting precision immunoengineering and technological innovation as promising pathways toward more targeted, personalized, and durable disease-modifying therapies.
- Open Access
- 7 April 2026
- Published by Elsevier in SSRN Electronic Journal
Multifunctional hybrid lipid-polymeric nanoparticle enabling resveratrol and siRNA co-delivery for enhanced cutaneous wound repair
Chronic ulcers impose a significant global healthcare burden due to the limited availability of effective and durable treatments. Impaired spatial and temporal coordination of immune, epithelial, and endothelial responses contributes to persistent inflammation and defective tissue repair. To address this complexity, in this study, we report the rational design and characterization of a hybrid lipid–polymeric nanoparticle (HLPN) platform for prolonged topical co-delivery of resveratrol (RSV), targeting oxidative and inflammatory pathways, and siRNA against matrix metalloproteinase-9 (siMMP9), a key mediator of chronicity. The optimized HLPNs exhibited a mean diameter of ~180 nm, low polydispersity (PDI <0.2), and positive surface charge (~20 mV), with high RSV encapsulation efficiency (98%). Surface-complexed siRNA remained protected from RNase degradation for up to 24 h. Incorporation of HLPNs into a hydroxyethylcellulose hydrogel resulted in favorable colloidal properties, leading to enhanced penetration and retention of the therapeutic agents in both intact and barrier-impaired skin. HLPN effectively mediated the cellular uptake of siRNA, resulting in significant MMP-9 gene silencing (≈11-36.5-fold reduction). The co-delivery system also markedly decreased intracellular reactive oxygen species and pro-inflammatory cytokines TNF-α and IL-6 (≈3.8 and 12.9-fold). Importantly, lipopolysaccharide-induced impairment of fibroblast migration was reversed, with the HLPN-RSV-siMMP9 formulation increasing cell migration compared with untreated inflamed controls. Together, these findings demonstrate that the multifunctional HLPN platform developed enables effective multimodal modulation of inflammatory and proteolytic pathways, representing a promising nanotherapeutic strategy for chronic wound management.
- 7 April 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessMultifunctional hybrid lipid-polymeric nanoparticle enabling resveratrol and siRNA co-delivery for enhanced cutaneous wound repair
Chronic ulcers impose a significant global healthcare burden due to the limited availability of effective and durable treatments. Impaired spatial and temporal coordination of immune, epithelial, and endothelial responses contributes to persistent inflammation and defective tissue repair. To address this complexity, in this study, we report the rational design and characterization of a hybrid lipid–polymeric nanoparticle (HLPN) platform for prolonged topical co-delivery of resveratrol (RSV), targeting oxidative and inflammatory pathways, and siRNA against matrix metalloproteinase-9 (siMMP9), a key mediator of chronicity. The optimized HLPNs exhibited a mean diameter of ~180 nm, low polydispersity (PDI <0.2), and positive surface charge (~20 mV), with high RSV encapsulation efficiency (98%). Surface-complexed siRNA remained protected from RNase degradation for up to 24 h. Incorporation of HLPNs into a hydroxyethylcellulose hydrogel resulted in favorable colloidal properties, leading to enhanced penetration and retention of the therapeutic agents in both intact and barrier-impaired skin. HLPN effectively mediated the cellular uptake of siRNA, resulting in significant MMP-9 gene silencing (≈11-36.5-fold reduction). The co-delivery system also markedly decreased intracellular reactive oxygen species and pro-inflammatory cytokines TNF-α and IL-6 (≈3.8 and 12.9-fold). Importantly, lipopolysaccharide-induced impairment of fibroblast migration was reversed, with the HLPN-RSV-siMMP9 formulation increasing cell migration compared with untreated inflamed controls. Together, these findings demonstrate that the multifunctional HLPN platform developed enables effective multimodal modulation of inflammatory and proteolytic pathways, representing a promising nanotherapeutic strategy for chronic wound management.
- 18 September 2020
- Published by Taylor & Francis in Expert Opinion on Drug Delivery
- Vol. 17 (12) , 1781-1805
Advances in lyotropic liquid crystal systems for skin drug delivery
Lyotropic liquid crystals (LLCs) are organized mesophases with intermediate properties between liquids and solids. The LLC and its liquid crystalline nanoparticles (LCNPs) have attracted great inte...
- 18 September 2020
- Published by Taylor & Francis in Expert Opinion on Drug Delivery
- Vol. 17 (12) , 1781-1805
Advances in lyotropic liquid crystal systems for skin drug delivery
Lyotropic liquid crystals (LLCs) are organized mesophases with intermediate properties between liquids and solids. The LLC and its liquid crystalline nanoparticles (LCNPs) have attracted great inte...
- 14 February 2020
- Published by Springer Nature in Drug Delivery and Translational Research
- Vol. 10 (3) , 646-660
Nanostructured lipid carrier co-delivering tacrolimus and TNF-α siRNA as an innovate approach to psoriasis
Since psoriasis is an immuno-mediated skin disease, long-term therapies are necessary for its treatment. In clinical investigations, tacrolimus (TAC), a macrolide immunosuppressive inhibitor of calcineurin, arises as an alternative for the treatment of psoriasis, acting in some cytokines involved in the pathogenesis of the disease. Here, we aim to study the psoriasis treatment with TAC and siRNA for one of most cytokines expressed in psoriasis, the TNF-α. A multifunctional nanostructure lipid carrier (NLC) was developed to co-delivery TAC and siRNA. Results showed that the particle size and zeta potential were around 230 nm and + 10 mV, respectively. The release study demonstrated a controlled release of TAC, and the permeation and retention profile in the skin tissue show to be promising for topical application. The cell viability and uptake in murine fibroblast presented low toxicity associated to uptake of NLC in 4 h, and finally, the in vivo animal model demonstrates the efficiency of the NLC multifunctional, exhibiting a reduction of the cytokine TNF-α expression about 7-fold and presenting a synergic effect between the TAC and TNF-α siRNA. The developed system was successfully to treat in vivo psoriatic animal model induced by imiquimod and the synergic combination was reported here for the first time.
- 14 February 2020
- Published by Springer Nature in Drug Delivery and Translational Research
- Vol. 10 (3) , 646-660
Nanostructured lipid carrier co-delivering tacrolimus and TNF-α siRNA as an innovate approach to psoriasis
Since psoriasis is an immuno-mediated skin disease, long-term therapies are necessary for its treatment. In clinical investigations, tacrolimus (TAC), a macrolide immunosuppressive inhibitor of calcineurin, arises as an alternative for the treatment of psoriasis, acting in some cytokines involved in the pathogenesis of the disease. Here, we aim to study the psoriasis treatment with TAC and siRNA for one of most cytokines expressed in psoriasis, the TNF-α. A multifunctional nanostructure lipid carrier (NLC) was developed to co-delivery TAC and siRNA. Results showed that the particle size and zeta potential were around 230 nm and + 10 mV, respectively. The release study demonstrated a controlled release of TAC, and the permeation and retention profile in the skin tissue show to be promising for topical application. The cell viability and uptake in murine fibroblast presented low toxicity associated to uptake of NLC in 4 h, and finally, the in vivo animal model demonstrates the efficiency of the NLC multifunctional, exhibiting a reduction of the cytokine TNF-α expression about 7-fold and presenting a synergic effect between the TAC and TNF-α siRNA. The developed system was successfully to treat in vivo psoriatic animal model induced by imiquimod and the synergic combination was reported here for the first time.
- 1 January 2020
- Published by Elsevier in Advanced Drug Delivery Reviews
- Vol. 153, 109-136
Nanotechnology approaches in the current therapy of skin cancer
- 1 January 2020
- Published by Elsevier in Advanced Drug Delivery Reviews
- Vol. 153, 109-136
Nanotechnology approaches in the current therapy of skin cancer
- Open Access
Intradermal Application of Crotamine Induces Inflammatory and Immunological Changes In Vivo
Crotamine is a single-chain polypeptide with cell-penetrating properties, which is considered a promising molecule for clinical use. Nevertheless, its biosafety data are still scarce. Herein, we assessed the in vivo proinflammatory properties of crotamine, including its local effect and systemic serum parameters. Sixty male Wistar rats were intradermically injected with 200, 400 and 800 µg crotamine and analyzed after 1, 3 and 7 days. Local effect of crotamine was assessed by determination of MPO and NAG activities, NO levels and angiogenesis. Systemic inflammatory response was assessed by determination of IL-10, TNF-α, CRP, NO, TBARS and SH groups. Crotamine induced macrophages and neutrophils chemotaxis as evidenced by the upregulation of both NAG (0.5–0.6 OD/mg) and MPO (0.1–0.2 OD/mg) activities, on the first and third day of analysis, respectively. High levels of NO were observed for all concentrations and time-points. Moreover, 800 μg crotamine resulted in serum NO (64.7 μM) and local tissue NO (58.5 μM) levels higher or equivalent to those recorded for their respective histamine controls (55.7 μM and 59.0 μM). Crotamine also induced a significant angiogenic response compared to histamine. Systemically, crotamine induced a progressive increase in serum CRP levels up to the third day of analysis (22.4–45.8 mg/mL), which was significantly greater than control values. Crotamine (400 μg) also caused an increase in serum TNF-α, in the first day of analysis (1095.4 pg/mL), however a significant increase in IL-10 (122.2 pg/mL) was also recorded for the same time-point, suggesting the induction of an anti-inflammatory effect. Finally, crotamine changed the systemic redox state by inducing gradual increase in serum levels of TBARS (1.0–1.8 μM/mL) and decrease in SH levels (124.7–19.5 μM/mL) throughout the experimental period of analysis. In summary, rats intradermally injected with crotamine presented local and systemic acute inflammatory responses similarly to histamine, which limits crotamine therapeutic use on its original form.
Open AccessIntradermal Application of Crotamine Induces Inflammatory and Immunological Changes In Vivo
Crotamine is a single-chain polypeptide with cell-penetrating properties, which is considered a promising molecule for clinical use. Nevertheless, its biosafety data are still scarce. Herein, we assessed the in vivo proinflammatory properties of crotamine, including its local effect and systemic serum parameters. Sixty male Wistar rats were intradermically injected with 200, 400 and 800 µg crotamine and analyzed after 1, 3 and 7 days. Local effect of crotamine was assessed by determination of MPO and NAG activities, NO levels and angiogenesis. Systemic inflammatory response was assessed by determination of IL-10, TNF-α, CRP, NO, TBARS and SH groups. Crotamine induced macrophages and neutrophils chemotaxis as evidenced by the upregulation of both NAG (0.5–0.6 OD/mg) and MPO (0.1–0.2 OD/mg) activities, on the first and third day of analysis, respectively. High levels of NO were observed for all concentrations and time-points. Moreover, 800 μg crotamine resulted in serum NO (64.7 μM) and local tissue NO (58.5 μM) levels higher or equivalent to those recorded for their respective histamine controls (55.7 μM and 59.0 μM). Crotamine also induced a significant angiogenic response compared to histamine. Systemically, crotamine induced a progressive increase in serum CRP levels up to the third day of analysis (22.4–45.8 mg/mL), which was significantly greater than control values. Crotamine (400 μg) also caused an increase in serum TNF-α, in the first day of analysis (1095.4 pg/mL), however a significant increase in IL-10 (122.2 pg/mL) was also recorded for the same time-point, suggesting the induction of an anti-inflammatory effect. Finally, crotamine changed the systemic redox state by inducing gradual increase in serum levels of TBARS (1.0–1.8 μM/mL) and decrease in SH levels (124.7–19.5 μM/mL) throughout the experimental period of analysis. In summary, rats intradermally injected with crotamine presented local and systemic acute inflammatory responses similarly to histamine, which limits crotamine therapeutic use on its original form.